



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
Rockville MD 20857

December 21, 1999

Nicholas M. Fleischer, R.Ph., Ph.D.  
Director of Biopharmaceutics  
The Weinberg Group, Inc.  
1220 Nineteenth Street, NW, Suite 300  
Washington, DC 20036-2400

Dear Dr. Fleischer:

Your petition requesting the Food and Drug Administration to declare that the drug product Acyclovir Dispersible Tablets, 200 mg are suitable for submission as an abbreviated new drug application was received by this office on December 20, 1999. It was assigned docket number 99P-5452/CP 1 and it was filed on December 20, 1999. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for tiling is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

A handwritten signature in black ink, reading "Lyle D. Jaffe", is written over a faint rectangular stamp.

Lyle D. Jaffe  
Dockets Management Branch

99P-5452

ACK 1